Approaches for the development of drugs for treatment of obesity and metabolic syndrome

Pharmacology, Toxicology and Pharmaceutical Science

• Reuptake Inhibitor 100%
• Pharmacotherapy 100%
• Metabolic Syndrome X 100%
• Antiobesity Drugs 100%
• Malignant Neoplasm 50%
• Musculoskeletal Disease 50%
• Receptor 50%
• Drug Development 50%
• Beloranib 50%
• Tetrahydrolipstatin 50%
• Sibutramine 50%
• Rimonabant 50%
• Amfebutamone Plus Naltrexone 50%
• Adipocytokine 50%
• Amfebutamone Plus Zonisamide 50%
• Tesofensine 50%
• Methionyl Aminopeptidase 2 50%
• Side Effect 50%
• Cannabinoid Receptor Antagonist 50%
• Lorcaserin 50%
• Comorbidity 50%
• Cardiovascular Disease 50%

Medicine and Dentistry

• Metabolic Syndrome 100%
• 5-HT Receptors 100%
• Drug Therapy 66%
• Reuptake Inhibitor 66%
• Antiobesity Drugs 66%
• Malignant Neoplasm 33%
• Cardiovascular Disease 33%
• Body Mass Index 33%
• Receptor 33%
• Sibutramine 33%
• Lipid Absorption 33%
• Adipocytokine 33%
• Tesofensine 33%
• Diabetes 33%
• Side Effect 33%
• Mediator 33%
• Lorcaserin 33%
• Amfebutamone Plus Naltrexone 33%
• Amfebutamone Plus Zonisamide 33%
• Rimonabant 33%
• Central Nervous System 33%
• Orlistat 33%
• Beloranib 33%
• Cannabinoid Receptor Antagonist 33%
• Methionyl Aminopeptidase 2 33%
• Energy Metabolism 33%
• Musculoskeletal Disease 33%
• Comorbidity 33%
• Cardiovascular System 33%